['lymphoma, mantle-cell']
['ibrutinib']

        Inclusion Criteria:

          -  Diagnosis of mantle cell lymphoma ( MCL) must include morphology and expression of
             either cyclin D1 in association with one B-cell marker (for example, cluster of
             differentiation [CD] CD19, CD20, or paired box [PAX5]) or evidence of t(11;14) as
             assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase
             chain reaction (PCR)

          -  Received at least 1 prior lines of therapy for MCL (separate lines of therapy are
             defined as single or combination therapies that are either separated by disease
             progression or by a greater than 6-month treatment-free interval)

          -  At least 1 measurable site of disease according to the Revised Response Criteria for
             Malignant Lymphoma (that is, the site of disease must be greater than 1.5 centimeter
             [cm] in the long axis regardless of short axis measurement or greater than 1.0 cm in
             the short axis regardless of long axis measurement, and clearly measurable in 2
             perpendicular dimensions)

          -  Have documented failure to achieve at least partial response (PR) with, or documented
             disease progression after, the most recent anti-MCL treatment regimen

          -  Eastern Cooperative Oncology Group performance status score of 0 or 1

        Exclusion Criteria:

          -  Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer
             antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation
             therapy within 3 weeks, or major surgery within 4 weeks of the first dose of study
             drug

          -  Prior treatment with ibrutinib or other Bruton's Tyrosine Kinase (BTK) inhibitors

          -  More than 5 prior lines of therapy for MCL (separate lines of therapy are defined as
             single or combination therapies that are either separated by disease progression or by
             a greater than 6-month treatment-free interval)

          -  Known central nervous system (CNS) lymphoma

          -  Woman who is pregnant, breast-feeding, or planning to become pregnant within 1 month
             after the last dose of study drug or is a man who plans to father a child while
             enrolled in this study or within 3 months after the last dose of study drug
      